Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.
Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.
Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.
Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.
Pasithea Therapeutics (NASDAQ: KTTA) has announced that it will present updated interim clinical data from its ongoing Phase 1 trial of PAS-004, a next-generation macrocyclic MEK inhibitor, at the 2025 ASCO Annual Meeting in Chicago. The presentation will take place on June 2, 2025, from 1:30 – 4:30 PM CDT.
The trial focuses on patients with MAPK pathway driven advanced solid tumors and has shown promising results through cohorts 4A and 4B, demonstrating clinical activity, target engagement, and a favorable safety profile. PAS-004 is being developed for treating neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications.
The Phase 1 clinical trial (NCT06299839) is designed as a multi-center, open-label, dose escalation 3+3 study, evaluating safety, tolerability, pharmacokinetic, pharmacodynamic, and preliminary efficacy in patients with documented RAS, NF1 or RAF mutations, or those who have failed BRAF/MEK inhibition.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive progress in its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancers. The Safety Review Committee recommended advancing to Cohort 6 with a 30mg capsule dose following review of Cohort 5 data.
Key highlights include:
- No dose-limiting toxicities (DLTs) observed across 19 patients
- Zero instances of rash reported during the DLT period
- Strong enrollment demand with Cohort 6 patients already identified
The trial (NCT06299839) is a multi-center, open-label, dose escalation study evaluating PAS-004's safety, tolerability, and preliminary efficacy in patients with MAPK pathway driven advanced solid tumors. The company plans to release additional safety, pharmacokinetic, and pharmacodynamic data in the coming weeks.
Pasithea Therapeutics (NASDAQ: KTTA) has announced its participation in the upcoming 2025 CAGLA NeauxCancer Conference, a leading global oncology forum scheduled for March 27-29, 2025, in New Orleans.
The company's Vice President of Business Development, Mathew Lazarus, will present on March 28 at 11:00 AM CDT at The Roosevelt Hotel. His presentation will focus on PAS-004, the company's next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 (NF1) and other cancer indications.
The presentation will include interim data from their ongoing Phase 1 study, covering safety, tolerability, and pharmacokinetic (PK) results in advanced cancer patients with MAPK pathway-driven tumors. Lazarus will also discuss Pasithea's progress in clinical development and their strategy to revolutionize cancer and NF1 treatment.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive safety review recommendations for its Phase 1 clinical trial of PAS-004, advancing to cohort 5 with a 22mg capsule dose. The trial, evaluating a next-generation macrocyclic MEK inhibitor for neurofibromatosis type 1 (NF1) and other cancers, showed no dose-limiting toxicities in cohort 4A (15mg capsule) patients.
Notably, none of the 14 patients treated with PAS-004 (12 capsule, 2 tablet formulations) experienced rash, a common side effect with competitor MEK inhibitors that often leads to treatment discontinuation. The drug demonstrates a half-life exceeding 60 hours and substantial exposure levels. The ongoing multi-center, open-label study (NCT06299839) evaluates safety, tolerability, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors with RAS, NF1, or RAF mutations.
Pasithea Therapeutics (NASDAQ: KTTA) has expanded its Phase 1 clinical trial for PAS-004, a next-generation macrocyclic MEK inhibitor, by opening three new sites in Eastern Europe. The trial now includes locations in Romania and Bulgaria, operating alongside four existing U.S. sites. The company has completed initial dosing of three patients in Cohort 4A (15mg capsule) and is currently recruiting for Cohort 4B (4mg tablet).
The ongoing trial is a multi-center, open-label, dose-escalation study evaluating PAS-004's safety, tolerability, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors. The company expects to present interim safety and pharmacokinetic data from Cohorts 4A and 4B in Q1 2025.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive safety results from its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor. The Safety Review Committee recommended advancing to cohort 4 with a 15mg capsule dose, following no dose-limiting toxicities in the first 9 patients. Notably, no rash was observed, which is a common adverse event with competitor MEK inhibitors. The company will add cohort 4b to test a commercial formulation. PAS-004 demonstrates advantages over first-generation MEK inhibitors, including a longer half-life of 70 hours enabling once-daily dosing, and consistent plasma levels at steady-state.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a $5 million private placement priced at-the-market under Nasdaq rules. The offering includes the sale of 1,219,513 shares of common stock (or pre-funded warrants) with accompanying Series A and short-term Series B warrants at $4.10 per share. Both warrant series have an exercise price of $3.85 per share, with Series A expiring in 5 years and Series B in 18 months.
The closing is expected around September 30, 2024, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Pasithea plans to use the net proceeds for working capital and general corporate purposes. The securities are offered under Section 4(a)(2) of the Securities Act and/or Regulation D and have not been registered, limiting their sale in the United States.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive initial data from its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, for advanced cancer treatment. The trial, conducted at four U.S. sites, showed promising results in safety, tolerability, pharmacokinetics (PK), and preliminary efficacy.
Key findings include:
- No treatment-related adverse events or dose-limiting toxicities observed
- Long half-life of ~70 hours, supporting once-daily or less frequent oral dosing
- Constant target inhibition while avoiding peak plasma toxicities
- A patient with stage 3 colon cancer achieved prolonged stable disease
The company believes PAS-004 demonstrates a differentiated MEK inhibitor profile, potentially outperforming current inhibitors in safety, dosing frequency, and efficacy for treating neurofibromatosis type 1 (NF1) and other cancer indications.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has successfully completed long-term chronic toxicity studies for its lead candidate PAS-004, a next-generation macrocyclic MEK inhibitor. The studies, conducted in rats (6 months) and dogs (9 months), confirm the safety profile observed in prior 28-day toxicity studies. Key findings include:
1. Establishment of 0.5 mg/kg as the no adverse effect level (NOAEL) in dogs, the most sensitive species.
2. Consistent safety profile at doses correlating with significant pathway engagement.
3. Similar adverse event profile and equivalent NOAEL for crystalline PAS-004 compared to the original amorphous formulation.
These results support chronic patient dosing and highlight PAS-004's potential as a best-in-class MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancer indications. Pasithea plans to share initial interim pharmacokinetic and pharmacodynamic data from its Phase 1 clinical study later this quarter.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, the Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital, brings extensive expertise in Neurofibromatosis type 1 (NF1) research and treatment. This appointment aligns with Pasithea's development of PAS-004, a next-generation macrocyclic MEK inhibitor for NF1 treatment.
Dr. Brown's experience, particularly in cutaneous and plexiform neurofibromas, will contribute to Pasithea's upcoming Phase 1/2a clinical trial for NF1. She highlighted PAS-004's potential advantages, including a long half-life, superior therapeutic index, cleaner safety profile, and once-daily dosing, which could represent a significant advancement in NF1 treatment.
